Schizophrenia

Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics

This qualitative study (n=19) of people with non-affective psychotic disorders who had used psychedelics found that, although there were some overlaps in altered thinking and meaning-making, most participants felt psychedelic experiences were not closely similar to psychosis. The authors conclude that psychedelics may be poor models of many psychotic symptoms, and that describing psychedelic effects as broadly psychosis-like may be misleading.

Authors

  • Peter Hendricks
  • Christopher Nicholas
  • Heith Copes

Published

International Journal of Mental Health and Addiction
individual Study

Abstract

Despite a long-standing interest in the potential similarities between psychedelic and psychotic experiences, no recent research has systematically explored the subjective overlap between these states in individuals who have experienced both. To provide rich accounts of potential overlaps and distinctions, we conducted semi-structured interviews with 19 individuals diagnosed with non-affective psychotic disorders who had used psychedelics. Participants described perceived similarities and differences between the acute effects of psychedelics and their experiences during psychosis. The study used reflexive thematic analysis to analyze the transcripts. Participants identified several points of contrast, including sensory alterations, emotional experience, altered thinking, meaning attribution, sense of control, and self experience. Although some similarities were acknowledged, particularly in terms of altered thinking and meaning attribution, most participants reported that psychedelic experiences did not closely resemble their experiences with psychosis. When asked which drug most resembled their psychotic symptoms, the majority endorsed cannabis, followed by dissociative anesthetics and stimulants. Psychedelics may not accurately model many symptoms of psychosis despite impacting similar domains of experience. These findings have implications for potential tolerability studies of psychedelics in people with psychotic disorders and suggest that interpreting psychedelic-induced experiences as broadly psychosis-like may be misleading.

Available with Blossom Pro

Research Summary of 'Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics'

Blossom's Take

Psychedelics were originally seen as compounds that mimicked psychosis. That is, within the scientific community, after encountering LSD (and psilocybin) through Hofmann and Sandoz. Now, over half a century later, this interview study brings this concept before the current scientific standards and finds it lacking in precision (noting cannabis, dissociative anesthetics, and stimulants were all closer matches).

Introduction

Non-affective psychotic disorders such as schizophrenia have long been compared with the acute effects of serotonergic psychedelics because both can alter perception, thought, and self-experience. Earlier work often relied on indirect or historical comparisons, and while some studies suggested psychedelics can induce psychosis-like phenomena, it remained unclear how similar these states actually feel to people who have experienced both. The paper also notes that current psychedelic trials usually exclude people with personal or family histories of psychotic disorders, partly because psychedelics are assumed to be strongly psychotomimetic, yet that assumption has not been well examined from a lived-experience perspective. M. and colleagues therefore set out to explore, through qualitative interviews, how individuals with lived experience of non-affective psychotic disorders and psychedelic use describe similarities and differences between the two states. The study aimed to clarify whether psychedelic experiences are subjectively perceived as psychosis-like, which features overlap, and what this might mean for future tolerability studies, clinical support, and broader interpretations of psychedelics as psychotomimetics.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (22)

Papers cited by this study that are also in Blossom

Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

Carhart-Harris, R. L., Brugger, S., Nutt, D. J. et al. · Journal of Psychopharmacology (2013)

The paradoxical psychological effects of lysergic acid diethylamide (LSD)

Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)

253 cited
Extended difficulties following the use of psychedelic drugs: A mixed methods study

Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)

123 cited
Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)

Serotonin research: contributions to understanding psychoses

Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)

Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers

Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)

187 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

Show all 22 references
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Experiences of psychedelic drug use among people with psychotic symptoms and disorders: Personal growth and mystical experiences

Torre, J. T. L., Gallo, J., Mahammadli, M. et al. · Journal of Psychedelic Studies (2024)

6 cited
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders

La Torre, J. T., Mahammadli, M., Faber, S. et al. · International Journal of Mental Health and Addiction (2023)

11 cited
Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison

Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)

A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

296 cited
Psychedelic use and psychiatric risks

Simonsson, O., Goldberg, S. B., Chambers, R. et al. · Psychopharmacology (2023)

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)

Adolescent Psychedelic Use and Psychotic or Manic Symptoms

Simonsson, O., Mosing, M. A., Osika, W. et al. · JAMA Psychiatry (2024)

24 cited
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model

Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance

Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.